The 18 references in paper E. Shmelev I., Е. Шмелев И. (2014) “Современные возможности коррекции одышки у больных хронической обструктивной болезнью легких // Current opportunities to improve dyspnea in patients with chronic obstructive pulmonary disease” / spz:neicon:pulmonology:y:2013:i:6:p:79-84

1
Al7Shair K., Mullerova H., Locantore N.W. et al.Fatigue significantly associated with COPD exacerbations: data from the ECLIPSE study. Am. J. Respir. Crit. Care Med. 2011; 183: A3974.
(check this in PDF content)
2
Global strategy for diagnosis, management, and prevention of COPD. February 2013.
(check this in PDF content)
3
Чучалин А.Г. (ред.). Руководство по респираторной медицине. М.: ГЭОТАР, 2007; т. 1–2.
(check this in PDF content)
4
Troyer A., Brunko E., Leduc D., Jammes Y.Reflex inhibition of canine inspiratory intercostals by diaphragmatic tension receptors. J. Physiol. (Lond.) 1999; 514 (1): 255–263.
(check this in PDF content)
5
Similowski T., Yan S., Gauthier A.P. et al. Contractile properties of the human diaphragm during chronic hyperinflation. N. Engl. J. Med. 1991; 325: 917–923.
(check this in PDF content)
6
Tashkin D.P. The role of small airway inflammation in asthma. Allergy Asthma Proc. 2002; 23 (4): 233–242.
(check this in PDF content)
7
Hamid Q.A., Mak J.C., Sheppard M.N. et al.Localization of beta-2-adrenoceptor messenger RNA in human and rat lung using in situ hybridization: correlation with receptor autoradiography. Eur. J. Pharmacol. 1991; 206 (2): 133–138.
(check this in PDF content)
8
Adcock I.M., Gilbey T., Gelder C.M. et al. Glucocorticoid receptor localization in normal and asthmatic lung. Am. J. Respir. Crit. Care Med. 1996; 154 (3, Pt 1): 771–782.
(check this in PDF content)
9
Lipworth B.J.Targets for inhaled treatment. Respir. Med. 2000; 94 (Suppl. D): S13–S16.
(check this in PDF content)
10
Tulic M.K., Christodoulopoulos P., Hamid Q.Small airway inflammation in asthma. Respir. Res. 2001; 2 (6): 333–339.
(check this in PDF content)
11
Di Marco F., Milic7Emili J., Boveri B. et al.Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD. Eur. Respir. J. 2003; 21: 86–94.
(check this in PDF content)
12
Acerbi D., Brambilla G., Kottakis I. Advances in asthma and COPD management: delivering CFC-free inhaled therapy using Modulite technology. Pulm. Pharmacol. Ther. 2007; 20 (3): 290–303.
(check this in PDF content)
13
Criee C.P., Meyer T., Petro W. et al.In vitro comparison of two delivery devices for administering formoterol: Foradil P and formoterol ratiopharm single-dose capsule inhaler. J. Aerosol. Med. 2006; 19 (4): 466–472.
(check this in PDF content)
14
Meyer T., Brand P., Ehlich H. et al. Deposition of Foradil P in human lungs: comparison of in vitro and in vivo data. J. Aerosol. Med. 2004; 17 (1): 43–49.
(check this in PDF content)
15
Brand P., Meyer T., Weuthen T. et al. Lung deposition of radiolabeled tiotropium in healthy subjects and patients with chronic obstructive pulmonary disease. J. Clin. Pharmacol. 2007; 47 (10): 1335–1341.
(check this in PDF content)
16
Haussermann S., Acerbi D., Brand P. et al.Lung deposition of formoterol HFA (Atimos / Forair) in healthy volunteers, asthmatic and COPD patients. J. Aerosol. Med. 2007; 20 (3): 331–341.
(check this in PDF content)
17
Terzano C., Petroianni A., Conti V. et al. Rational timing of combination therapy with tiotropium and formoterol in moderate and severe COPD. Respir. Med. 2008; 102 (12): 1701–1707.
(check this in PDF content)
18
Tzani P., Crisafulli E., Nicolini G. et al. Effects of beclomethasone / formoterol fixed combination on lung hyperinflation and dyspnea in COPD patients. Int. J. Chron. Obstruct. Pulm. Dis. 2011; 6: 503–509. Информация об авторе
(check this in PDF content)